[go: up one dir, main page]

EA201200017A1 - Новая кристаллическая форма пемироласта - Google Patents

Новая кристаллическая форма пемироласта

Info

Publication number
EA201200017A1
EA201200017A1 EA201200017A EA201200017A EA201200017A1 EA 201200017 A1 EA201200017 A1 EA 201200017A1 EA 201200017 A EA201200017 A EA 201200017A EA 201200017 A EA201200017 A EA 201200017A EA 201200017 A1 EA201200017 A1 EA 201200017A1
Authority
EA
Eurasian Patent Office
Prior art keywords
pemirolast
crystal form
new crystal
sodium
new
Prior art date
Application number
EA201200017A
Other languages
English (en)
Other versions
EA025865B1 (ru
Inventor
Анет Перльберг
Мартин Фиртельхауз
Ульрика Розенштрём
Карол Хорват
Original Assignee
Кардоз Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кардоз Аб filed Critical Кардоз Аб
Publication of EA201200017A1 publication Critical patent/EA201200017A1/ru
Publication of EA025865B1 publication Critical patent/EA025865B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Secondary Cells (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Dental Preparations (AREA)

Abstract

Предложена натриевая соль пемироласта в форме гемигидрата.
EA201200017A 2009-06-16 2010-06-15 Кристаллическая форма пемироласта EA025865B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US18735509P 2009-06-16 2009-06-16
US18734809P 2009-06-16 2009-06-16
PCT/GB2010/001168 WO2010146348A2 (en) 2009-06-16 2010-06-15 New crystalline form of pemirolast

Publications (2)

Publication Number Publication Date
EA201200017A1 true EA201200017A1 (ru) 2013-10-30
EA025865B1 EA025865B1 (ru) 2017-02-28

Family

ID=43264726

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201200017A EA025865B1 (ru) 2009-06-16 2010-06-15 Кристаллическая форма пемироласта

Country Status (31)

Country Link
US (3) US20120157415A1 (ru)
EP (2) EP2443120B1 (ru)
JP (2) JP5722317B2 (ru)
KR (2) KR20170049645A (ru)
CN (1) CN102596202B (ru)
AR (1) AR077915A1 (ru)
AU (1) AU2010261540B2 (ru)
BR (1) BRPI1015559A2 (ru)
CA (1) CA2765408A1 (ru)
CY (1) CY1118413T1 (ru)
DK (1) DK2443120T3 (ru)
EA (1) EA025865B1 (ru)
ES (1) ES2613059T3 (ru)
HR (1) HRP20170023T1 (ru)
HU (1) HUE032978T2 (ru)
IL (1) IL216670A (ru)
LT (1) LT2443120T (ru)
ME (1) ME02685B (ru)
MX (1) MX2011013676A (ru)
NZ (1) NZ596747A (ru)
PL (1) PL2443120T3 (ru)
PT (1) PT2443120T (ru)
RS (1) RS55558B1 (ru)
SA (1) SA114350792B1 (ru)
SG (1) SG176295A1 (ru)
SI (1) SI2443120T1 (ru)
SM (2) SMT201700085T1 (ru)
TW (1) TWI504599B (ru)
UY (1) UY32711A (ru)
WO (2) WO2010146348A2 (ru)
ZA (1) ZA201109045B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2498779A1 (en) * 2009-11-13 2012-09-19 Cardoz AB Pemirolast for the treatment of systemic low grade inflammation
US20160243122A1 (en) 2014-10-23 2016-08-25 Rspr Pharma Ab Use of pemirolast in the treatment of acute asthma
WO2016102941A1 (en) 2014-12-22 2016-06-30 Rspr Pharma Ab New combination of pemirolast and montelukast
GB201518831D0 (en) 2015-10-23 2015-12-09 Rspr Pharma Ab New use
AU2017340594B2 (en) * 2016-10-03 2020-09-10 Brivention Pharmaceutical (Shanghai) Inc. Composition comprising combination of TRH analog with arundic acid, and pharmaceutically acceptable salt of arundic acid

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4122274A (en) * 1977-05-25 1978-10-24 Bristol-Myers Company 3-Tetrazolo-5,6,7,8-substituted-pyrido[1,2-a]pyrimidin-4-ones
JP2504788B2 (ja) 1987-11-10 1996-06-05 東京田辺製薬株式会社 ９−メチル−３−（１Ｈ−テトラゾ―ル−５−イル）−４Ｈ−ピリド［１，２−ａ］ピリミジン−４−オンカリウム塩の水性製剤
JP2837449B2 (ja) * 1989-08-11 1998-12-16 東京田辺製薬株式会社 ピリド［１，２―ａ］ピリミジン誘導体の製造法
ITMI20011764A1 (it) 2001-08-10 2003-02-10 Dinamite Dipharma Spa Metodo per l'ottenimento del pemirolast ad elevata purezza
KR101361441B1 (ko) 2005-09-16 2014-02-10 다이이찌 산쿄 가부시키가이샤 광학활성인 디아민 유도체 및 그의 제조방법
CN101610765A (zh) * 2006-12-18 2009-12-23 卡多兹公司 用于治疗炎症的新组合物
WO2008075028A1 (en) * 2006-12-20 2008-06-26 Cardoz Ab New combination for use in the treatment of inflammatory disorders

Also Published As

Publication number Publication date
EP2443120A2 (en) 2012-04-25
ES2613059T3 (es) 2017-05-22
EP3141549A1 (en) 2017-03-15
BRPI1015559A2 (pt) 2016-04-26
CA2765408A1 (en) 2010-12-23
AU2010261540A2 (en) 2012-01-19
PL2443120T3 (pl) 2017-04-28
IL216670A0 (en) 2012-02-29
WO2010146348A9 (en) 2012-05-03
US20140329839A1 (en) 2014-11-06
KR20120032530A (ko) 2012-04-05
US9006431B2 (en) 2015-04-14
SI2443120T1 (sl) 2017-04-26
US20170202839A1 (en) 2017-07-20
EP2443120B1 (en) 2016-11-02
AU2010261540A1 (en) 2012-01-19
PT2443120T (pt) 2017-02-08
JP2015120750A (ja) 2015-07-02
ME02685B (me) 2017-06-20
AR077915A1 (es) 2011-10-05
UY32711A (es) 2011-01-31
JP2012530118A (ja) 2012-11-29
JP5722317B2 (ja) 2015-05-20
RS55558B1 (sr) 2017-05-31
LT2443120T (lt) 2017-02-10
SA114350792B1 (ar) 2015-11-10
EA025865B1 (ru) 2017-02-28
CY1118413T1 (el) 2017-06-28
WO2010146341A2 (en) 2010-12-23
DK2443120T3 (en) 2017-01-09
HUE032978T2 (hu) 2017-11-28
NZ596747A (en) 2014-01-31
SG176295A1 (en) 2012-01-30
ZA201109045B (en) 2013-05-29
TWI504599B (zh) 2015-10-21
IL216670A (en) 2017-02-28
KR20170049645A (ko) 2017-05-10
MX2011013676A (es) 2012-02-08
WO2010146348A3 (en) 2011-03-03
US20120157415A1 (en) 2012-06-21
SMT201700085T1 (it) 2017-03-08
SMT201700085B (it) 2017-03-08
CN102596202B (zh) 2015-01-21
WO2010146341A3 (en) 2011-03-03
HRP20170023T1 (hr) 2017-03-10
AU2010261540B2 (en) 2016-04-14
CN102596202A (zh) 2012-07-18
WO2010146348A2 (en) 2010-12-23
TW201100422A (en) 2011-01-01

Similar Documents

Publication Publication Date Title
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
HRP20181695T1 (hr) Kristalni oblik inhibitora benzilbenzena sglt2
HN2012000263A (es) Derivados n1-sulfonil-5-fluoropirimidinona
CL2012002979A1 (es) Derivados de n3-sustituido-n1-sulfonil-5-fluorpirimidinona.
CR20120295A (es) Triazolopiridinas
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
EA201270254A1 (ru) Производные 5-фторпиримидинона
BRPI1010795A2 (pt) compostos antivirais
UY33958A (es) Inhibidores de la glucosilceramida sintasa
CR20120297A (es) Espironucleósidos uracílicos oxetánicos
CL2011000098A1 (es) Uso de una betadefensina de mamifero para tratar enfermedad inflamatoria.
HRP20170222T1 (hr) Kristalni oblik karbamoil-cikloheksan derivata
BRPI1007815A2 (pt) substratos porosos hidrofílicos
UY33930A (es) Inhibidores novedosos de quinasas
UY33754A (es) Monobactamas
BR112013028039A2 (pt) composição de cimento
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
ECSP12011652A (es) Derivados de 5-fluoro-2-oxopirimidinona-1 (2h)-carboxamida substituida-n1
EA201200017A1 (ru) Новая кристаллическая форма пемироласта
CL2009001973S1 (es) Mostrador.
CL2008001014A1 (es) Procedimiento para preparar comprimidos de dihidrocloruro de prampipexol.
MA32474B1 (fr) Nouveaux derives de (piperazinyl ponte) -1-alcanone et leur utilisation comme inhibiteurs de p75
EP2538960A4 (en) surfactant
TN2012000381A1 (en) 2-aldoximino-5-fluoropyrimidine derivatives
BR112012004828A2 (pt) transportador de pentose

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM RU